Clinical Studies on the Efficacy and Safety of Xinsuning Capsules in the Treatment of Atrial fibrillation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2025000708

Enrollment

Unknown

Registered

2025-04-11

Start date

2025-04-30

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

treatment group:Xinsu Ning+Conventional Western Medicine Treatment

control group:Conventional Western Medicine Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with atrial fibrillation aged = 18 years and clinically diagnosed are classified into paroxysmal persistent persistent and permanent atrial fibrillation according to clinical classification.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Total Atrial Fibrillation Burden;	—

Secondary

Measure	Time frame
Cicas haee cfie sinoranes;ingle Symptom Resolution Rate;(Blood routine urine index liver function kidney function);chesodeer of atrial fibrilation;HR HRV Pmax Pd;Duration of atrial fibrillation attack;	—

Countries

China

Contacts

Public ContactYifei Wang

Shandong University of Traditional Chinese Medicine Affiliated Hospital

15853150460@163.com15853150460

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026